ProQR Therapeutics N.V. and Galapagos N.V. Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology

ProQR Therapeutics N.V. announced that it has entered into a research collaboration agreement with Galapagos N.V. Under the agreement the two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets selected by Galapagos. The targets that will be pursued in the collaboration and financial details about the collaboration are not disclosed.